Detalles de la búsqueda
1.
Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer.
N Engl J Med
; 386(12): 1132-1142, 2022 03 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-35179323
2.
Extended Safety and Tolerability of Darolutamide for Nonmetastatic Castration-Resistant Prostate Cancer and Adverse Event Time Course in ARAMIS.
Oncologist
; 2024 Feb 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-38394384
3.
Nonmetastatic, Castration-Resistant Prostate Cancer and Survival with Darolutamide.
N Engl J Med
; 383(11): 1040-1049, 2020 09 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-32905676
4.
Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer.
N Engl J Med
; 380(13): 1235-1246, 2019 03 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-30763142
5.
Broad spectrum of regorafenib activity on mutant KIT and absence of clonal selection in gastrointestinal stromal tumor (GIST): correlative analysis from the GRID trial.
Gastric Cancer
; 25(3): 598-608, 2022 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-35050442
6.
Efficacy and safety of darolutamide in Japanese patients with nonmetastatic castration-resistant prostate cancer: a sub-group analysis of the phase III ARAMIS trial.
Int J Clin Oncol
; 26(3): 578-590, 2021 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-33226524
7.
Regorafenib for advanced gastrointestinal stromal tumors following imatinib and sunitinib treatment: a subgroup analysis evaluating Japanese patients in the phase III GRID trial.
Int J Clin Oncol
; 20(5): 905-12, 2015 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-25655899
8.
Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial.
Lancet
; 381(9863): 295-302, 2013 Jan 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-23177515
9.
Deep and Durable Prostate-specific Antigen Response to Darolutamide with Androgen Deprivation Therapy and Docetaxel, and Association with Clinical Outcomes for Patients with High- or Low-volume Metastatic Hormone-sensitive Prostate Cancer: Analyses of the Randomized Phase 3 ARASENS Study.
Eur Urol
; 2024 Apr 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-38644146
10.
Comparison of Cerebral Blood Flow in Regions Relevant to Cognition After Enzalutamide, Darolutamide, and Placebo in Healthy Volunteers: A Randomized Crossover Trial.
Target Oncol
; 18(3): 403-413, 2023 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-37103658
11.
Darolutamide Plus Androgen-Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the Phase III ARASENS Trial.
J Clin Oncol
; 41(20): 3595-3607, 2023 07 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-36795843
12.
Safety and tolerability of long-term treatment with darolutamide in patients with metastatic castration-resistant prostate cancer.
Prostate Cancer Prostatic Dis
; 2023 Oct 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-37884613
13.
Darolutamide and health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: An analysis of the phase III ARAMIS trial.
Eur J Cancer
; 154: 138-146, 2021 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-34273811
14.
Evaluation of Clinically Relevant Drug-Drug Interactions and Population Pharmacokinetics of Darolutamide in Patients with Nonmetastatic Castration-Resistant Prostate Cancer: Results of Pre-Specified and Post Hoc Analyses of the Phase III ARAMIS Trial.
Target Oncol
; 14(5): 527-539, 2019 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-31571095
15.
Decreased absolute counts of T lymphocyte subsets and their relation to disease in squamous cell carcinoma of the head and neck.
Clin Cancer Res
; 10(11): 3755-62, 2004 Jun 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-15173082
16.
Expression of zeta in T cells prior to interleukin-2 therapy as a predictor of response and survival in patients with ovarian carcinoma.
Cancer Biother Radiopharm
; 17(6): 631-40, 2002 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-12537666
17.
Recent thymic emigrants and subsets of naive and memory T cells in the circulation of patients with head and neck cancer.
Clin Immunol
; 116(1): 27-36, 2005 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-15925829
18.
Preferential apoptosis of CD56dim natural killer cell subset in patients with cancer.
Eur J Immunol
; 33(1): 119-24, 2003 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-12594840
Resultados
1 -
18
de 18
1
Próxima >
>>